It seems reasonable to speculate that serum YKL-40 could be used for monitoring the efficiency and sufficiency of medical treatment of patients with CAD and thereby assist the clinician in reducing the high occurrence of fatal cardiovascular events. This evidence concerns the gene CHI3L1 and coronary artery disorder.